Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
POSVAX Alzheimer's Disease Vaccine
- Development stage
- Preclinical
- Lead developer
- POSVAX
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
POSVAX Alzheimer's Disease Vaccine is a virus-like particle (VLP)-based therapeutic vaccine candidate currently in preclinical development for the treatment of Alzheimer's disease. Developed using POSVAX's proprietary VLP platform, the vaccine utilizes yeast-derived viral capsid proteins that self-assemble into spherical particles. These particles are engineered to display specific Alzheimer's-related antigenic epitopes, intended to stimulate the patient's immune system to target and clear pathological proteins associated with the disease. A key feature of this platform is its ability to trigger a potent immune response without the requirement for additional adjuvants, as the VLP structure itself is designed to be highly immunogenic.
- Other names
- Alzheimer's Disease Vaccine (POSVAX)POSVAX VLP Alzheimer's vaccine
02
Targets
Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on POSVAX Alzheimer's Disease Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POSVAX Alzheimer's Disease Vaccine.